Broadening the Impact of Adjuvant Immunotherapy in Melanoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 572
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2022 AND VI 36 AND IP 9
Results: 11
1
2
Addition of Tremelimumab to Durvalumab Regimen Induces Greater Survival Outcomes in PD-L1--Negative mNSCLC.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 570
- Publication type:
- Article
3
Efficacy, Safety With Datopotamab Deruxtecan Plus Pembrolizumab Regimen Observed in Advanced NSCLC.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 570
- Publication type:
- Article
4
Tislelizumab Maintains OS Benefit vs Docetaxel in Previously Treated NSCLC.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 570
- Publication type:
- Article
5
Pembrolizumab Plus Lenvatinib Confers Promising Efficacy in Malignant Pleural Mesothelioma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 569
- Publication type:
- Article
6
ES-SCLC Responds to Temozolomide Plus Nivolumab Following Prior Chemotherapy.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 569
- Publication type:
- Article
7
Is Drug Price Negotiation a Concept Whose Time Has Come?
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 523
- By:
- Publication type:
- Article
8
Future Directions in the Management of Non--Small Cell Lung Cancer Harboring Driver Mutations.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 562
- By:
- Publication type:
- Article
9
Psycho-Oncology and the Relevance of a Biopsychosocial Screening Program.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 552
- By:
- Publication type:
- Article
10
Cancer Pain and Opioid Use Disorder.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 535
- By:
- Publication type:
- Article
11
Mark A. Socinski, MD, on Progression of Lung Cancer Treatment.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 9, p. 532
- By:
- Publication type:
- Article